Progesterone receptor membrane component 2 (Pgrmc2) mRNA was detected in the immature rat ovary. By 48 h after eCG, Pgrmc2 mRNA levels decreased by 40% and were maintained at 48 h post-hCG. Immunohistochemical studies detected PGRMC2 in oocytes and ovarian surface epithelial, interstitial, thecal, granulosa, and luteal cells. PGRMC2 was also present in spontaneously immortalized granulosa cells, localizing to the cytoplasm of interphase cells and apparently to the mitotic spindle of cells in metaphase. Interestingly, PGRMC2 levels appeared to decrease during the G 1 stage of the cell cycle. Moreover, overexpression of PGRMC2 suppressed entry into the cell cycle, possibly by binding the p58 form of cyclin dependent kinase 11b. Conversely, Pgrmc2 small interfering RNA (siRNA) treatment increased the percentage of cells in G 1 and M stage but did not increase the number of cells, which was likely due to an increase in apoptosis. Depleting PGRMC2 did not inhibit cellular 3 H-progesterone binding, but attenuated the ability of progesterone to suppress mitosis and apoptosis. Taken together these studies suggest that PGRMC2 affects granulosa cell mitosis by acting at two specific stages of the cell cycle. First, PGRMC2 regulates the progression from the G 0 into the G 1 stage of the cell cycle. Second, PGRMC2 appears to localize to the mitotic spindle, where it likely promotes the final stages of mitosis. Finally, siRNA knockdown studies indicate that PGRMC2 is required for progesterone to slow the rate of granulosa cell mitosis and apoptosis. These findings support a role for PGRMC2 in ovarian follicle development.
INTRODUCTION
Progesterone (P4) slows the rate at which granulosa cells and immortalized cells derived from granulosa cells, that is, spontaneously immortalized granulosa cells (SIGCs), undergo mitosis and apoptosis in vitro [1] [2] [3] [4] [5] [6] [7] [8] [9] . However, the classic nuclear progesterone receptor (PGR) does not mediate P4's actions because granulosa cells of growing follicles and SIGCs do not express PGR [10] [11] [12] [13] . Rather, P4's actions in these cells are mediated through PGR membrane component 1 (PGRMC1) [14, 15] as demonstrated by genetic manipulation of PGRMC1 levels in cultured cells [9, [14] [15] [16] [17] .
While PGRMC1 is the first member of the membraneassociated PGR family to be identified [18] , this family also includes other family members such as PGRMC2 [18] . The amino acid sequences of these two proteins are very similar with the major differences being observed distal to the transmembrane region (reviewed by Cahill [19] ). Although there are numerous publications on PGRMC1, to date there are only two published studies on the expression of PGRMC2 in the mammalian ovary and these are microarray-based. For example, microarray and subsequent PCR analysis reveals that Pgrmc2 is expressed at the time of follicle assembly in the neonatal rat ovary [20] . The other paper reports that granulosa cell Pgrmc2 mRNA levels are elevated in women with diminished ovarian reserve [21] . Interestingly, these women develop fewer follicles in response to gonadotropin treatment [21] . Taken together, these two studies imply that PGRMC2 plays a role in both the formation and development of ovarian follicle. Given the limited amount of data regarding the expression and function of PGRMC2 in the ovary, the present study was designed to determine the expression of Pgrmc2 in the gonadotropin-primed immature rat ovary, freshly isolated rat granulosa cells, and SIGCs. Subsequent studies were then undertaken to determine whether PGRMC2 1) influences the rate of SIGC mitosis, 2) binds 3 H-P4, and/or 3) mediates P4's actions on mitosis and apoptosis.
MATERIALS AND METHODS
All the reagents were purchased from Sigma Chemical Co. unless specified otherwise. Additional information regarding the antibodies used in these studies is presented in Supplemental Table S1 (Supplemental Data are available online at www.biolreprod.org).
Collection and Processing of Immature Rat Ovaries after Gonadotropin Treatment
Immature female Sprague-Dawley rats between 22 to 25 days of age were obtained from the colony at Washington State University. A group of four immature control rats was treated i.p. with saline for 48 h and then euthanized by carbon dioxide exposure and cervical dislocation. A second group of nine rats was injected i.p with 5 international units equine chorionic gonadotropin (eCG) (EMD Millipore). Four of these rats were euthanized and the ovaries collected 48 h later. The remaining five rats were injected i.p. with 5 international units human chorionic gonadotropin (hCG) and 48 h later were euthanized and the ovaries prepared for PGRMC2 analysis. This protocol was approved by the Institutional Animal Care and Use Committee at Washington State University. For all the treatment groups, one ovary was fixed in 4% paraformaldehyde, paraffin embedded, and processed for immunohistochemical localization of PGRMC2 as described below. Total RNA was isolated from the remaining ovary from each rat using Trizol (Life Technologies) and stored at À808C until analyzed for Pgrmc2 mRNA.
Granulosa Cell and SIGC Culture
For the granulosa cell culture studies, immature female Sprague-Dawley rats (21 days of age) were obtained from Charles River Laboratory. At 22-25 days of age, rats were euthanized by carbon dioxide exposure followed by cervical dislocation. The ovaries were removed, trimmed of fat, and the follicles punctured with a 26 g needle to release the granulosa cells [14] . The granulosa cells were isolated and plated at 4 3 10 5 /ml in a 35 mm 2 dish (Becton Dickinson) with cover glass on the bottom. This protocol was approved by the University of CT Health Center Institutional Animal Care and Use Committee.
SIGCs, which were derived from granulosa cells of rat preovulatory follicles [22] , were maintained in culture as previously described [14, 15] . Unless otherwise stated, 4 3 10 5 cells were placed in 35 mm 2 dishes with or without a cover glass in 2 ml of DMEM/F12 with 5% fetal bovine serum (FBS).
In the experiments involving the effects of 1 lM P4, cells were cultured in DMEM/F12 supplemented with 5% steroid-free FBS (Hyclone).
Immunochemical Localization of PGRMC2
To localize PGRMC2 within the rat ovary, paraffin-embedded ovaries were sectioned at 5 lm. The sections were deparaffinized, and endogenous peroxidase activity was quenched by exposure to hydrogen peroxide. Then the sections were boiled for 10 min in 10 mM sodium citrate buffer (pH 6.0) and subsequently incubated overnight at 48C with combined primary (1:100, PGRMC2 clone 3C11) and secondary (1:2000; Life Technologies) antibodies, which were previously incubated for 2 h at 378C in blocking solution containing normal mouse serum to eliminate nonspecific binding. Sections were then washed in PBS, incubated in horseradish peroxidase-conjugated streptavidin for 45 min at room temperature (Vector Laboratories), washed in PBS, and incubated with 3,3 0 -diaminobenzidine substrate. Sections were then methyl-green counterstained. PGRMC2 was revealed as a brown precipitate. As a negative control, ovarian sections were incubated using the same protocol but with nonimmune immunoglobulin G (IgG) replacing the primary antibody.
For immunocytochemical localization studies, granulosa cells and SIGCs that were plated on cover glass were fixed with 4% paraformaldehyde, washed in PBS, permeablized with 0.1% Triton X-100, and incubated in 5% normal goat serum for 1 h at room temperature. The cells were then incubated overnight at 48C with a mouse monoclonal anti-PGRMC2 antibody (Clone 3C11, 1:200 in 0.1% bovine serum albumin/PBS). Negative controls were incubated without the primary antibody. Cells were then washed with PBS and incubated for 1 h with goat anti-mouse antibody tagged with either Alexa Fluor 546 (red fluorescence) or Alexa Fluor 350 (blue fluorescence) (Molecular Probes) to detect the primary PGRMC2 antibody. The use of the secondary antibody to detect PGRMC2 was dependent on the experimental objective.
Changes in PGRMC2 Expression During the Cell Cycle
To determine if PGRMC2 expression was cell cycle dependent, SIGCs were infected with fluorescence ubiquitination cell cycle indicator (FUCCI) (P36237; Life Technologies). Briefly, SIGCs were infected with FUCCI (20 viral particles per cell) and cultured at 378C for 24 h. FUCCI utilizes a baculovirus (BacMan 2.0) to infect cells with DNA that encodes the ubiquitination domains of either the geminin-green fluorescent protein (GFP) fusion protein or cytolethal distending toxins (cdt)-red fluorescent protein (RFP) fusion protein [23] . To assess the efficiency of the baculovirus infection, SIGCs were separately infected with a baculovirus (BacMan 2.0) that encodes an actin-GFP fusion protein (C10582; Life Technologies).
Note that cdt and geminin are expressed in the G 1 and G 2 stages, respectively, while both are expressed in the S stage of the cycle [23] . Twentyfour hours after infection, the cells were fixed and stained for PGRMC2 as described above using an Alexa350 (blue) secondary antibody. Using this protocol, nonfluorescent cells with interphase nuclei were considered to be in the G 0 stage, red fluorescent cells were in the G 1 stage, and green fluorescent cells were in the G 2 stage. S stage cells were observed as fluorescing yellow after merging the green and red fluorescent signals. The fluorescent intensity of the blue signal was used to estimate the level of PGRMC2. The relationship between PGRMC2 expression and each stage of the cell cycle was determined by fluorescent microscopy.
Genetic Manipulation of Pgrmc1 and/or Pgrmc2 Levels
To assess the effect of PGRMC2 on entry into the cell cycle, SIGCs were simultaneously infected with the baculovirus that encodes the cdt-RFP fusion protein and transfected with either the GFP empty vector (control) or GFP-PGRMC2 expression construct using Lipofectamine 2000 as previously described [17] . The GFP expression construct, which encodes human Pgrmc2, was provided by Dr. Martin Wehling (University of Heidelberg at Mannheim) [24] . Its identity was confirmed by DNA sequencing. After infection/ transfection the cells were cultured in 5% steroid-free FBS in DMEM overnight. After 24 h of culture, cultures were examined by fluorescent microscopy, and for each experiment, 200 cells that expressed the GFP protein were identified. Then these GFP-expressing cells were observed under the RFP filter set to determine if they were in the G 1 /S stage of the cell cycle. The percentage of transfected cells in the G 1 /S stage was calculated for each treatment group.
To determine the effect of depleting PGRMC2, SIGCs were cultured for 24 h and then transfected using Lipofectamine 2000 with Pgrmc1 or Pgrmc2 siRNA (small interfering RNA). The siRNA sequences for rat Pgrmc1 and Pgrmc2 siRNAs were CCUGGUAAUUGGCAGUUGGtt (253165; Life Technologies) and GGAAAUGCAGUUUAAAGAAtt (s168258; Life Technologies), respectively. As a control, a scramble siRNA control (AM4611; Life Technologies) was used. Twenty-four hours after transfection, the cells from one 35 mm 2 dish were harvested, replated into two 35 mm 2 dishes, and cultured with DMEM/F12 supplemented with 5% FBS for an additional 24 h. The cultures were then used either to 1) measure Pgrmc1 and Pgrmc2 mRNA levels by real-time PCR, 2) monitor PGRMC2 by immunocytochemistry, or 3) assess the percentage of cells at each stage of the cell cycle using the FUCCI probe.
Pgrmc1 and Pgrmc2 mRNA Measurements by Real-Time PCR RNA was isolated from the SIGCs using RNeasy Plus Mini-Kit (Qiagen) per the manufacturer's instructions and converted to cDNA [17] . A 20 ll . The real-time PCR reaction was run in the CFX96 real-time PCR system. The cycling steps for enzyme activation were 30 sec at 958C, denaturation for 5 sec at 958C, and annealing/extension at 608C for 1-10 sec; 40 cycles were conducted. Gene expression was evaluated using Bio-Rad CFX96 software. Pgrmc1 and Pgrmc2 levels were normalized to actin and expressed as a percentage of the scramble treatment group.
For Pgrmc2 expression analysis in rat ovaries, total RNA was first treated with DNase I to eliminate contaminating DNA and then purified using RNeasy Plus Mini-Kit (Qiagen) per the manufacturer's instructions. RNA was next converted to cDNA using Superscript II (Life Technologies). A 20 ll reaction was set up for each sample in which 1.5 ng cDNA, Syber Green PCR Master Mix, Pgrmc2 forward primer (5 0 d TCGAGAGTGGGAAATGCAGT 3 0 ), and Pgrmc2 reverse primer (5 0 d GCTCTTCCCCTGGCTTTAGG 3 0 ) were included. The ribosomal protein Rpl13a was used as an internal control (5 0 d AAAGGTGGTGGTTGTACGCT 3 0 and 5 0 AGACGGGTTGGTGTTCATCC 3 0 ). The real-time PCR reaction was run in the CFX96 real-time PCR system. The cycling steps for enzyme activation were 10 min at 958C, denaturation for 15 sec at 958C, and annealing/extension at 608C for 1 min; 40 cycles were conducted. Gene expression was evaluated using Bio-Rad CFX96 software where Pgrmc2 levels were normalized to Rpl13a and expressed as a percentage of the nongonadotropin-treated control.
Identification of Cyclin Dependent Kinase 11b as a PGRMC2 Binding Partner
To gain insight into PGRMC2's mode of action, SIGCs were transfected with GFP-PGRMC2. Twenty-four hours later, GFP-PGRMC2 and associated proteins were isolated as described in our previously published protocol [15] . Briefly, the transfected SIGCs were lysed in cold RIPA buffer and the supernatant collected. The GFP-PGRMC2 fusion protein and associated proteins were isolated using the anti-GFP microbeads and the protocol and reagents provided by Miltenyi Biotec. The isolate was then sent to Yale GRIFFIN ET AL.
University Keck Foundation for Biotechnology Mass Spectrometry and Protein Identification facility. The PGRMC2-associated proteins were identified by liquid chromatography-mass spectrometry/mass spectrometry after enzymatic (trypsin) digestion. This analysis revealed a potential interaction with the cyclin-dependent kinase, CDK11b. The presence of GFP-PGRMC2 in the isolate was confirmed by Western blot analysis using the GFP antibody (1:1000; Cell Signaling) or the PGRMC2 antibody (1:200) .
The interaction between GFP-PGRMC2 and CDK11b was confirmed using two approaches. First, additional experiments were conducted in which GFP-PGRMC2 and associated proteins were isolated using anti-GFP microbeads as described above. The isolate was used in a Western blot analysis that was probed with a CDK11b antibody (sc-928; Santa Cruz Biotechnology). Similar experiments were conducted in which GFP-empty vector was transfected and the GFP isolate run on Western blot and probed with CDK11b antibody.
The second approach involved colocalization and an in situ proximity ligation assay (PLA) that were conducted as described in our previous publication [6] . The colocalization of PGRMC2 and CDK11b was conducted using the PGRMC2 and CDK11b antibodies and the immunocytochemical protocol outlined previously. Because colocalization is not sufficient to demonstrate a protein-protein interaction, an in situ PLA (Duolink II; OLINK Bioscience) was conducted according to the manufacturer's instructions. In this assay, the same primary antibodies to PGRMC2 and CDK11b were used, but the secondary antibodies were labeled with complementary oligonucleotide strands that generate a signal (a red fluorescent spot) only when the two proteins are bound to each other (http://www.olink.com/).
H-Progesterone Binding to Intact SIGCs
For these studies SIGCs were plated in 96-well culture plates (4 3 10 4 /well) and transfected with either scramble, Pgrmc1, or Pgrmc2 siRNA as previously described [17, 25] with the exception that the cultures were not replated after 24 h of culture. After 48 h of culture, 3 H-P4 binding studies were conducted, and the amount of 3 H-P4 specifically bound to SIGCs was determined as previously described [13, 26] . Specific 3 H-P4 binding was expressed as a percentage of the scramble control. The binding experiments were repeated four times and values are means 6 SEM.
Assessment of Cell Proliferation and Apoptosis
SIGCs were plated and transfected with Pgrmc2 siRNA as described above with the exception that after the initial 24 h culture period the cells were replated in 35 mm 2 dishes in which the bottom plate was scored with a diamond pen to identify four quadrants. Two hours after replating, the culture medium was removed and the dishes were washed gently with DMEM/F12 to remove any cells that were not firmly attached. The culture medium was then replaced with medium with or without supplemental P4 (1 lM) and pictures taken of each quadrant. After 22 h of culture, pictures were taken of the same quadrants. The number of cells in each quadrant at 2 and 24 h of culture was counted and used to calculate fold increase in cell number. Cells were also fixed and stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) in order to calculate the percentage of apoptotic cells. A cell was considered apoptotic if its nucleus was condensed and/or fragmented [17] .
Statistical Analysis
All the experiments were replicated at least three times unless stated otherwise. All the animals were assigned to treatment groups randomly. Values from each experiment were pooled to generate a mean 6 SEM. Differences between treatment groups were assessed by Student t test if only the means of two groups were compared or by an ANOVA followed by the Fisher LSD post hoc test if more than two treatment groups were compared. Regardless of the analysis, P 0.05 was considered to be significantly different.
RESULTS
Ovarian levels of Pgrmc2 mRNA were highest prior to gonadotropin treatment. By 48 h after eCG, the ovarian levels of Pgrmc2 mRNA decreased by '40% and were maintained at this level after hCG treatment (Fig. 1A) . Immunohistochemical studies revealed that PGRMC2 was present in all the cell types within the ovary with the most pronounced staining observed within the corpora lutea (Fig. 1, B and E) and interstitial tissue after eCG-hCG treatment (Fig. 1B) . Intense staining for PGRMC2 was also present in the surface epithelial cells of ovaries prior to and after gonadotropin treatment (Fig. 1C) .
Staining was also evident in the thecal cells, granulosa cells, and oocytes of preantral (Fig. 1C) and antral follicles (Fig. 1D) . Staining for PGRMC2 was also observed in luteal cells present after eCG-hCG treatment (Fig. 1E) . Note that the brown staining, which revealed PGRMC2, was not observed in luteal cells when the PGRMC2 antibody was replaced by nonimmune IgG in the staining protocol, demonstrating the specificity of the immunohistochemical detection of PGRMC2 (Fig. 1F) . Similarly when IgG replaced the PGRMC2 antibody, brown staining was not observed in thecal, granulosa, surface epithelial and interstitial cells, or oocytes (Supplemental Fig.  S1 ).
Immunocytochemical staining also detected PGRMC2 in both freshly isolated granulosa cells from nongonadotropinprimed immature rat ovaries ( Fig. 2A) and SIGCs (Fig. 2B) . The PGRMC2 immunocytochemical protocol was specific because only minimal fluorescence was detected in the absence of the PGRMC2 antibody (Fig. 2C) or after PGRMC2 siRNA treatment (compare Fig. 7C with 7B) .
These studies demonstrated that PGRMC2 predominately localized to the cytoplasm. In metaphase, PGRMC2's localization was consistent with it being associated with the mitotic spindle (Fig. 2B inset) . For interphase cells, the intensity of PGRMC2 staining was variable, suggesting the possibility that PGRMC2 expression was cell cycle dependent.
To test this possibility, we opted to infect cells with the FUCCI because it can precisely identify cells in G 1 unlike DNA-based fluorescence-activated cell sorting (FACS) analysis, which groups G 0 /G 1 stage cells together. Although the use of FUCCI to monitor changes in the cell cycle is relatively new, its application has been well documented (See Supplemental Data on FUCCI). However, one limitation of using FUCCI is that FUCCI-infected cells in the G 0 stage do not fluoresce, which is a limitation only if the infection efficiency is low. In order to estimate infection efficiency, cells were infected using baculovirus (BacMan 2.0) that encodes actin-GFP fusion protein. Twenty-four hours after infection with the baculovirus encoding actin-GFP, an average of 86% of the cells fluoresced green, indicating that they were expressing the actin-GFP fusion protein (Supplemental Fig. S2 ). This infection rate is in line with the estimated 90% infection rate provided by the manufacturer. Given that baculovirus (BacMan 2.0) is used to infect cells with the FUCCI probe and therefore has the same infection rate as actin-GFP, it is estimated that 14% of the SIGCs would not be infected with the FUCCI probe. These noninfected cells would be distributed proportionately to cells in each stage of the cell cycle; thus, the error due to infection efficiency would appear to be relatively minor.
Given that this limitation would not significantly impair the ability to determine the stage of the cell cycle, SIGCs were infected with FUCCI; the DNA stained with Hoechst 33342 and the percent of cells in each stage of the cell cycle estimated by FACS using standard DNA-based or FUCCI-based analyses. As can be seen in Supplemental Figure S3A (Fig. 3A) . Note that the percent of cells in each stage of the cell cycle was similar regardless of whether the analysis was conducted using FACS or fluorescent microscope (Supplemental Fig. S3C) .
To define the relationship between the presence of PGRMC2 and the stage of the cell cycle, cells were infected A) The effect of sequential injections of eCG and hCG on the relative Pgrmc2 mRNA levels is shown. Values are expressed as the mean 6 SEM, and * indicates values that are significantly less than the 0 h control (P , 0.05). B) A low-power image of an eCG-hCG treated ovary stained for PGRMC2. The most intense brown staining, which indicates the presence of PGRMC2, was observed in the corpus luteum (CL) and interstitium (I), but thecal cells, granulosa cells, and oocytes also stained for PGRMC2. C) A preantral follicle form an immature rat ovary. PGRMC2 staining was detected in the oocyte as well as granulosa and thecal cells of this follicle. The ovarian surface epithelial cells were also intensely stained for PGRMC2 (arrow). A large antral follicle of an eCG-primed rat ovary is shown in D, which shows PGRMC2 staining in the oocyte, granulosa, and thecal cells. E) A higher power image of luteal cells taken from an eCG-hCG treated immature rat. Note that PGRMC2 was localized to the cytoplasm. F) A higher power image of luteal cells taken from an eCG-hCG treated immature rat that serves as a negative control because the PGRMC2 antibody was replaced with nonimmune IgG. Images taken at magnifications of 3100 (B), 3200 (C, D), and 3400 (E, F).
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with FUCCI and then stained for PGRMC2 using the Alexa Fluor 350-labeled secondary antibody (blue fluorescence), but not with DAPI, and examined under the fluorescent microscope. This analysis revealed that cells in the G 1 stage of the cell cycle (Fig. 3B ) appeared to express less PGRMC2 than those cells in G 0 (Fig. 3b) . Note that cells in S or G 2 had the same level of PGRMC2 expression as those cells in G 0 (compare Fig. 3C with 3c ). This cell cycle-dependent change in 
PGRMC2 EXPRESSION AND FUNCTION
PGRMC2 expression was also reflected in the semiquantitative measurements of the fluorescent intensity of PGRMC2 staining (Fig. 3E) .
To assess the localization of PGRMC2 in cells during mitosis, PGRMC2 was detected using a secondary antibody labeled with Alexa Fluor 546 (red fluorescence) and the chromosomes stained with DAPI (blue fluorescence). This analysis revealed that PGRMC2 appeared to localize to the mitotic spindle at all stages of mitosis, including metaphase (Fig. 2B inset) and anaphase (compare Fig. 3D with 3d) .
The transient suppression of PGRMC2 at the G 1 stage implied that the levels of PGRMC2 decrease in order to allow cells to enter the cell cycle. To test this hypothesis, PGRMC2 levels were increased by transfecting the cells with a GFP-PGRMC2 expression vector. Like endogenous PGRMC2, GFP-PGRMC2 was localized predominately in the cytoplasm (Fig. 4A) and was detected by Western blots that used isolate obtained after partial purification of the GFP-PGRMC2 fusion protein (Fig. 4B) . This analysis detected GFP-PGRMC2 as a single '55 kDa band using either the GFP antibody or the PGRMC2 antibody (Fig. 4B) . As seen in Figure 4C , overexpression of PGRMC2 reduced the percentage of cells that entered the G 1 /S stage of the cell cycle compared to the GFP empty vector control.
In an attempt to gain insight into the mechanism through which GFP-PGRMC2 suppressed entry into the cell cycle, proteins that interacted with GFP-PGRMC2 were identified using a mass spectrometric approach. This analysis revealed that CDK11b interacted with GFP-PGRMC2. CDK11b exists as an inactive or active form, detected as 110 and 58 kDa proteins, respectively [27] . Western blots using whole cell lysate detected the 58 kDa form (Fig. 5A ), but the 110 kDa form was occasionally detected depending on the duration of imaging. To confirm that CDK11b interacts with GFP-PGRMC2, GFP-PGRMC2 was transfected into cells and partially purified, and the purified GFP-PGRMC2 preparation used in a Western blot analysis. Probing this Western blot with the CDK11b antibody detected the 58 kDa form (Fig. 5B) . Note that in this experiment, staining with the GFP antibody not only detected the '55 kDa GFP-PGRMC2 fusion protein For this study, cells were transfected with GFP-PGRMC2 and a whole cell lysate was prepared. An aliquot was taken and used in the Western blot shown in A. The remaining lysate was used to partially purify GFP-PGRMC2 and associated proteins. Aliquots of the GFP-PGRMC2 isolate were run in Western blot protocols and probed with either the GFP antibody to detect PGRMC2 or the CDK11b antibody (B). B) The results of a similar study in which the cells were transfected with the EFP-empty vector. Note that in this study the GFP antibody detected a 27 kDa band, the expected kDa of GFP but bands were not observed when the CDK11b antibody was used. In this figure, lanes marked with a minus sign (À) indicate a negative control in which the primary antibody was omitted. Lanes marked with a plus sign (þ) indicate that the Western blot protocol included the primary antibody.
but also lower kDa forms that were assumed to be degraded forms of GFP-PGRMC2 (Fig. 5B) . Importantly similar experiments in which cells were transfected with the GFPempty vector did not detect either the 110 kDa or 58 kDa form of CDK11b (Fig. 5B) , thereby confirming the specificity of this GFP-PGRMC2 pull-down assay.
The interaction between endogenous PGRMC2 and CDK11b was also supported by colocalization studies that show both proteins localizing to the cytoplasm, with CDK11b also present with the nucleus (Fig. 6A-C) . That this staining was specific is demonstrated by omitting the primary antibodies (Fig. 6D) . Moreover, PLA, which detects proteinprotein interactions, clearly demonstrated that these two proteins interact (compare the number of red dots/cell in Fig.  6E with those in 6F, the negative control).
The role of PGRMC2 in regulating entry into the cell cycle was not only assessed by overexpression of PGRMC2 but also by depleting endogenous PGRMC2 using Pgrmc2 siRNA. As seen in Figure 7A , Pgrmc2 siRNA treatment reduced Pgrmc2 mRNA levels by '90% of scramble control without altering Pgrmc1 mRNA level. That Pgrmc2 siRNA treatment reduced PGRMC2 was confirmed by immunocytochemical analysis (compare Fig. 7B with 7C ). As seen in Figure 7D , depleting PGRMC2 reduced the percentage of cells in G 0 and increased the percentage in G 1 and M stages of the cell cycle (Fig. 7D) . Although the rate at which cells entered into the cell cycle was increased, the number of cells did not increase (Fig. 8B) . Rather, the rate of apoptosis increased (Fig. 8C) .
Finally, PGRMC2's role in mediating P4's actions was assessed by first determining if PGRMC2 affected the capacity of SIGCs to bind 3 H-P4. Data shown in Figure 8A confirmed that depleting Pgrmc1 mRNA by '90% (Fig. 7A) resulted in a corresponding decrease in the capacity of the cells to bind 3 H-P4 (Fig. 8A) . However, depleting Pgrmc2 siRNA by '90% did not alter the capacity of SIGCs to bind 3 H-P4 (Fig. 8A ). While depleting PGRMC2 did not reduce the capacity of SIGCs to bind 3 H-P4, the ability of P4 to suppress cell proliferation (Fig. 8B) and prevent apoptosis (Fig. 8C) was attenuated by Pgrmc2 siRNA treatment. Immunocytochemcial staining for PGRMC1 and CDK11B is shown in A (red fluorescence) and B (green fluorescence), respectively, while a colocalization (i.e., merged image yellow-orange fluorescence) of these two proteins is shown in C. A negative control in which the primary antibody was omitted is shown in D. These cells were also stained with DAPI to reveal the nucleus. D) Merged image of a negative control in which the red, green, and blue channels are merged. Note that there is no signal in either the red or green channels, indicating the specificity of this colocalization protocol. In E, the interaction between PGRMC2 and CDK11b is assessed by PLA, and the interaction between these two proteins was revealed by the presence of red dots. F) Negative control for the PLA in which one antibody (i.e., the PGRMC2 antibody) was omitted from the PLA protocol. Note the relative absence of red dots, which indicates that the PLA was specific.

DISCUSSION
PGRMC2 is the second member of the membraneassociated PGR family to be identified and to date has been shown to be expressed in several different cells and tissues, including mouse [28] , primate [29] , and bovine uterine endometrial cells [30] and oviductal epithelial cells [31] as well as placenta [32] and human granulosa/luteal cells obtained from patients undergoing in vitro fertilization [21] . In addition, PGRMC2 is expressed in peripheral blood mononuclear cells [33] , neonatal rat ovaries [20] , and both ovarian [24] and breast cancers [34] . PGRMC2 mRNA is also expressed in various hypothalamic nuclei [35] [36] [37] . The present study expands this list of cell types by demonstrating that PGRMC2 is expressed in all ovarian cell types within the immature rat ovary. Moreover, its ovarian expression is regulated by gonadotropin in that its level of expression is significantly reduced by eCG. Interestingly, hCG does not alter the eCG-induced level of expression. The physiological consequences of lowering ovarian PGRMC2 levels are not known. However, PGRMC2 levels within granulosa cells may affect the capacity of follicles to develop. This précis is based on the finding that Pgrmc2 mRNA levels in granulosa/luteal cells retrieved from in vitro fertilization patients that had a limited number of follicles develop in response to gonadotropin are elevated compared to other in vitro fertilization patients [21] .
To gain insight into the function of PGRMC2, a series of studies were conducted on both freshly isolated granulosa cells and cells derived from granulosa cells (i.e., SIGCs). In these ovarian cells, PGRMC2 localizes mainly to the cytoplasm as has been shown for ovarian cancer cells [24] . Interestingly, in granulosa cells and SIGCs, the level of expression is highly variable, suggesting the possibility that PGRMC2 is expressed in a cell cycle-dependent manner.
The standard method to identify cells in specific stages of the cell cycle is to use FACS to identify the cells in different stages of the cell cycle based on their DNA content. FACS can be used on living cells, but this is not a real-time assessment because considerable time is needed to analyze the large number of cells required for this analysis. More importantly, FACS-based identification of the stages of the cell cycle is typically based on DNA content, which cannot identify cells in G 0 verses G 1 because both have similar amounts of DNA.
Because of these limitations, the present studies use the FUCCI probe to assess the stage of the cell cycle. The FUCCI probe was developed in 2008 and has been used in 37 papers, of which 22 were published in 2012-2013 (See Supplemental Data on FUCCI). Although the FUCCI probe is relatively new, the use of the FUCCI probe is the best experimental tool to test the possibility that PGRMC2 is expressed in a cell cycledependent manner. This precise method of monitoring the stage of the cell cycle has three major advantages. First, FUCCI detects the stage of the cell cycle in living cells with the FUCCI signal changing as an individual cell progresses through the cell cycle. The second advantage is that the FUCCI signal can be fixed, allowing PGRMC2 to be detected by immunocytochemistry. The third advantage is that the FUCCI probe clearly distinguishes cells in G 1 from those in G 0 because FUCCI does not use DNA content to make this determination.
Through the combined use of the FUCCI probe and immunocytochemistry, the present study shows that PGRMC2 levels are apparently lower in the G 1 stage than the other stages of the cell cycle. This suggests that as cells enter into G 1 they express less PGRMC2. While these expression studies imply that the suppression of PGRMC2 is required for entry into the cell cycle, it must be appreciated that the PGRMC2 expression levels were made by immunofluorescence and are semiquantitative. Unfortunately, this is the only approach available at the present time because the PGRMC2 antibody does not work effectively when used in standard Western blot protocols.
In spite of this limitation, the concept that cell cycledependent expression of PGRMC2 plays an essential role in regulating entry into the cell cycle is supported by two additional lines of evidence. First, expressing GFP-PGRMC2 fusion protein maintains a prolonged elevation of PGRMC2 and subsequently inhibits entry into the cell cycle. Second, depleting endogenous PGRMC2 reduces the percentage of cells in the G 0 stage of the cell cycle and increases the percentage of cells in G 1 stage of the cell cycle. Thus taken together, these experimental approaches suggest that PGRMC2 regulates entry into the G 1 stage, positioning PGRMC2 to play a central role in regulating ovarian follicle development.
How PGRMC2 blocks entry into the cell cycle is unknown, but proteomic analysis indicates that GFP-PGRMC2 interacts with CDK11b, which is confirmed by independent GFP-PGRMC2 pull-down experiments shown in the present study. Moreover, colocalization and more importantly PLA studies indicate that endogenous PGRMC2 interacts with endogenous CDK11b. CDK11b is a serine/threonine kinase that is involved in cell cycle progression [38] . There are two isoforms of this kinase: a 110 (p110) and a 58 kDa (p58) form. The p58 form is active and required for normal cell cycle progression [38] . Specifically, increasing the level of the p58 form by overexpression results in early entry into the G 1 stage of the cell cycle. The p58 form of CDK11b binds cyclin D3 [39] , a G 1 /S stage-specific cyclin [40] . Binding cyclin D3 actives cyclin-dependent kinases [40] , thereby promoting progression through the G 1 /S stages of the cell cycle. It is possible then that PGRMC2 binding to the p58 form of CDK11b could inhibit CDK11b from binding cyclin D3. This would attenuate p58 CDK11b's activity and inhibit entry into the G 1 stage of the cell cycle. This concept is also consistent the present finding that PGRMC2 levels are reduced in the G 1 stage of the cell cycle, which would reduce the putative PGRMC2-CDK11b interaction, thus promoting p58 CDK11b-cyclin D3 interaction and cell cycle progression. Therefore, the proposed functional role of PGRMC2-CDK11b interaction provides a testable molecular framework that could define in part the mechanism through which PGRMC2 blocks the entry into the cell cycle.
While depleting PGRMC2 accelerates the rate at which SIGCs enter the cell cycle, it does not result in an increase in the number of cells. Rather, many PGRMC2-deplete SIGCs accumulate in metaphase, apparently failing to complete the final stages of mitosis. Moreover, it is likely that these cells undergo apoptosis. The reason for this likely relates to PGRMC2 localizing to the mitotic spindle. However, a definitive role for PGRMC2 during metaphase remains to be determined.
The present study also confirms that P4 suppresses granulosa cell proliferation and apoptosis [2, 3, 9] . Because P4's action is mediated at least in part through PGRMC1 [41] , it is possible that P4 also acts through PGRMC2 to suppress mitosis and apoptosis, given PGRMC2's similarity to PGRMC1 [18, 19] . There are several mechanisms through which PGRMC2 could mediate P4's effects. The mostly likely mechanism is that PGRMC2 binds P4 and subsequently activates a signal cascade that inhibits mitosis and apoptosis. However, this does not appear to be the case because depleting PGRMC2 does not affect the capacity of SIGCs to bind 3 H-P4. In contrast, depleting PGRMC1 essentially eliminates 3 H-P4 binding to SIGCs. This finding is consistent with the observation that partially purified PGRMC1 binds 3 H-P4, confirming that PGRMC1 is essential for P4 to bind SIGCs [15] . However, PGRMC1 may not directly bind 3 H-P4 but rather function through its interaction with PAQR7, also referred to as membrane progestin receptor alpha [42] . value that are significantly less than scramble control value (P , 0.05), while ** indicates a value that is significantly greater than the scramble control value (P , 0.05).
PGRMC2 EXPRESSION AND FUNCTION
Although PGRMC2 does not appear to bind P4, it is involved in mediating P4's capacity to suppress cell mitosis and apoptosis. This conclusion is based on the fact that in the relative absence of PGRMC2, P4 neither inhibits mitosis nor apoptosis even though P4 binds to PGRMC2-deplete SIGCs. These observations indicate that PGRMC2 is an essential component of the P4-signaling pathway and plays a role subsequent to P4 binding.
In summary, the present study demonstrates that PGRMC2 is expressed in granulosa cells and regulates mitosis by controlling both the rate at which cells enter the G 1 stage of the cell cycle and the successful completion of the metaphase. Furthermore, PGRMC2 plays a role in the P4 signal cascade that suppresses the rate of granulosa cell mitosis and apoptosis. Its precise role in this cascade is yet to be defined, but it is likely that PGRMC2 plays a role distal to P4 binding because depleting PGRMC2 does not alter 3 H-P4 binding to SIGCs. Given that PGRMC2 is expressed in granulosa cells of developing ovarian follicles and influences the rate of both mitosis and apoptosis, PGRMC2 appears to be positioned to play an important role in regulating ovarian follicle development, justifying further studies on PGRMC2's mechanism of action.
